ストックスクリーナーアプリを入手
1.765
2.02%
0.0349
アフターアワーズ：
1.79
0.025
+1.42%
前日終値:
$1.7301
開ける：
$1.78
24時間の取引高:
6,868
Relative Volume:
0.28
時価総額：
$71.13M
収益：
$1.88M
当期純損益:
$-15.57M
株価収益率:
-4.4125
EPS:
-0.4
ネットキャッシュフロー:
$-50.09M
1週間 パフォーマンス:
+1.73%
1か月 パフォーマンス:
+8.95%
6か月 パフォーマンス:
-7.11%
1年 パフォーマンス:
+81.96%
1日の値動き範囲:
$1.75
$1.79
1週間の範囲:
$1.66
$1.8689
52週間の値動き範囲:
$0.97
$4.00
Beyondspring Inc Stock (BYSI) Company Profile
BYSI を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BYSI
Beyondspring Inc
|
1.765 | 71.13M | 1.88M | -15.57M | -50.09M | -0.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Beyondspring Inc Stock (BYSI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-12-02 | ダウングレード | BofA Securities | Buy → Underperform |
| 2021-12-02 | ダウングレード | Jefferies | Buy → Hold |
| 2021-12-01 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2021-12-01 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2021-09-09 | 開始されました | Robert W. Baird | Outperform |
| 2021-08-04 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2021-04-05 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2021-01-11 | 開始されました | BofA Securities | Buy |
| 2020-12-29 | 開始されました | Evercore ISI | Outperform |
| 2020-02-07 | 開始されました | Jefferies | Buy |
| 2020-01-10 | 開始されました | Nomura | Buy |
| 2019-12-03 | 開始されました | William Blair | Outperform |
| 2019-07-10 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-04-30 | ダウングレード | Maxim Group | Buy → Hold |
| 2018-10-25 | 繰り返されました | Maxim Group | Buy |
すべてを表示
Beyondspring Inc (BYSI) 最新ニュース
SEED Therapeutics Secures FDA Rare Pediatric and Orphan Drug Designations for ST-01156 - MSN
BeyondSpring sells SEED Therapeutics shares for $35.4M - MSN
SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors - The Manila Times
BeyondSpring Announces $35.4 Million Sale of a Portion of - GlobeNewswire
SEED Receives FDA Rare Pediatric Disease and Orphan Drug - GlobeNewswire
BeyondSpring Cashes In $35M Stake as Cancer Drug Shows 89% Disease Control Rate - StockTitan
BeyondSpring (NASDAQ:BYSI) Shares Down 1.4%Here's Why - MarketBeat
Non-Small Cell Lung Cancer Clinical Trial Pipeline Boom as Over 100 Companies Leading the Charge in Research and Development | DelveInsight - The Malaysian Reserve
BeyondSpring Inc. Announces Change in Domestic Filing Status and Disclosure Channels to Disseminate Information - Defense World
BeyondSpring (BYSI) Stock Drops Amidst Biotech Sector Volatility - GuruFocus.com
Germ Cell Tumors Market to Register Significant Growth at a CAGR of 5.5% by 2034 | DelveInsight - The Malaysian Reserve
CTLA-4 Inhibitors Market to Advance at Moderate CAGR During the Study Period (2020-2034) | DelveInsight - The Malaysian Reserve
Retail investors reap multibagger gains by betting on these 29 - Oficjalny Portal Gminy Brzesko
BeyondSpring (NASDAQ:BYSI) Shares Up 4.5%Here's Why - MarketBeat
BeyondSpring (NASDAQ:BYSI) Trading 4.5% Higher – Here’s Why - Defense World
Non-small Cell Lung Cancer Treatment Market 2032: Clinical Trials, Medication, Prevalence, Incidence, Therapies, EMA, PDMA, FDA Approvals, and Companies by DelveInsight - The Globe and Mail
Non-small Cell Lung Cancer Treatment Market 2032: Clinical - openPR
Amazon.com Inc (AMZN-Q) QuotePress Release - The Globe and Mail
NK Cell Therapy Clinical Trial Pipeline Appears Robust With 140+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve
BeyondSpring Presents Updated Efficacy Results from a Phase - GlobeNewswire
BeyondSpring's Lung Cancer Drug Shows 89% Disease Control Rate in Phase 2 Trial | BYSI Stock News - StockTitan
ROS1 Inhibitors Market Booms as Demand for Targeted Cancer Therapies Escalates | DelveInsight - The Malaysian Reserve
BeyondSpring (BYSI) Stock Drops Amid Biotech Sector Volatility - GuruFocus.com
Neutropenia Treatment Market to hit USD 20.8 billion by 2032, says Global Market Insights Inc. - GlobeNewswire
BioWorld Cancer Index continues to decline amid broader market gains - BioWorld Online
Biotech Stocks Facing FDA Decision In November - RTTNews
BYSI (BeyondSpring) Cash From Discontinued Investing Activi - GuruFocus.com
Marshall Wace LLP Buys Shares of 10,538 Poseida Therapeutics, Inc. (NASDAQ:PSTX) - Defense World
Renaissance Technologies LLC Increases Stock Holdings in Mesa Air Group, Inc. (NASDAQ:MESA) - Defense World
CDK4/6 Inhibitors Market to Grow at Healthy Growth Rate by 2034 Owing to Expanded Usage of Approved Blockbuster CDK4/6 Inhibitors in Early-stage Breast Cancer and the Emergence of Newer Players in Other Indications | DelveInsight - PR Newswire UK
Caspase 8 Market Analysis, Trends, Growth, Research And Forecast 2030 - La Funcion mx
G-CSF (Granulocyte Colony Stimulating Factors) Market Size, Analysis, Trends, Overview And Forecast To 2033 - WhaTech
BYSI Sees Quick 5.39% Surge Amid Low Trading Volume - GuruFocus.com
BYSI: BeyondSpring Inc. Stock Surges 7.27% Amid Market Fluctuati - GuruFocus.com
BeyondSpring (BYSI) Stock Surges 6.83% Amid High Volume Trading - GuruFocus.com
Acadian Asset Management LLC Has $34,000 Stock Position in BeyondSpring Inc. (NASDAQ:BYSI) - Defense World
Chemotherapy Induced Neutropenia Market Size is Set for Rapid - openPR
BeyondSpring reports promising phase 2 NSCLC study results - Investing.com
BeyondSpring plinabulin, Merck Keytruda combo shows promise in NSCLC - MSN
BeyondSpring reports safer NSCLC therapy option - Investing.com India
BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024 - StockTitan
BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024 - StockTitan
BeyondSpring presented interim Phase 2 data on 303 Study - TipRanks
BeyondSpring Presents Efficacy/Safety Results from a Phase - GlobeNewswire
BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase - GlobeNewswire
BeyondSpring (NASDAQ:BYSI) Trading Up 3.3% - MarketBeat
BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-Type... - Markets Insider
BeyondSpring announces Dublin-3 final phase 3 efficacy data - TipRanks
BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-Type with Concurrent Publication in the Lancet Respira - GlobeNewswire
Beyondspring Inc (BYSI) 財務データ
収益
当期純利益
現金流量
EPS
5.49%
0.79%
大文字化:
|
ボリューム (24 時間):